# schizophrenia in adults FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/schizophrenia-in-adults

> No upcoming FDA catalysts in schizophrenia in adults; 4 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| April 28, 2023 | [UZEDY (risperidone) FDA approval](https://sec-api.dev/pdufa/risperidone) | TEVA | schizophrenia in adults | completed, approved | "UZEDY (risperidone) extended-release injectable suspension was approved by the FDA on April 28, 2023 for the treatment of schizophrenia in adults, and was launched in the U.S. in May 2023." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/818686/000119312526381899/d153033dex991.htm)) |
| September 26, 2024 | [Royalty Pharma plc PDUFA date](https://sec-api.dev/companies/rprx/catalysts) | RPRX | schizophrenia in adults | scheduled | "The NDA for KarXT for the treatment of schizophrenia in adults was accepted for review by FDA, with a PDUFA date of September 26, 2024." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1802768/000180276825000010/rprx-20241231.htm)) |
| February 20, 2026 | [BYSANTITM (milsaperidone) FDA approval](https://sec-api.dev/pdufa/milsaperidone) | VNDA | schizophrenia in adults | completed, approved | "On February 20, 2026, Vanda Pharmaceuticals Inc. ("Vanda") issued a press release announcing that the U.S. Food and Drug Administration has approved BysantiTM (milsaperidone) for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults and the treatment of schizophrenia in adults." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1347178/000162828026010376/vnda-20260220.htm)) |
| October 8, 2026 | [WELTRUZATM (olanzapine) FDA approval](https://sec-api.dev/pdufa/olanzapine) | TEVA | schizophrenia in adults | completed, approved | "NDA219007 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20261008, review_priority STANDARD; sponsor_name TEVA; product WELTRUZA (OLANZAPINE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA219007%22)) |

## Drugs

- [UZEDY (risperidone)](https://sec-api.dev/pdufa/risperidone) (TEVA)
- [BYSANTITM (milsaperidone)](https://sec-api.dev/pdufa/milsaperidone) (VNDA)
- [WELTRUZATM (olanzapine)](https://sec-api.dev/pdufa/olanzapine) (TEVA)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/schizophrenia-in-adults.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "schizophrenia in adults FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/schizophrenia-in-adults

```bibtex
@misc{secapidev_indications_schizophrenia_in_adults_20261116,
  title        = {schizophrenia in adults FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/schizophrenia-in-adults}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_schizophrenia_in_adults_20261116","title":"schizophrenia in adults FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/schizophrenia-in-adults","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
